Participant flow

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract · Source last updated 2020-03-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. cetuximab: given IV

   id

   FG000

   title

   Arm I (Treatment)

2. description

   Patients receive regular follow-up care

   id

   FG001

   title

   Arm II (Control)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         5

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

16 participants did not have biopsy proven dysplasia as required by protocol and were not randomized to treatment.

recruitment Details

Study enrolled patients with premalignant lesions of the Head and Neck with mild, moderate or severe dysplasias

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice